Adaptive Biotechnologies ADPT Mrd Business — Sales & Marketing
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Adaptive Biotechnologies in its filing.
Tagged under the XBRL concept us-gaap:SellingAndMarketingExpense.
The official record: Adaptive Biotechnologies’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about Adaptive Biotechnologies's mrd business — sales & marketing.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Adaptive Biotechnologies's mrd business — sales & marketing?
- Adaptive Biotechnologies (ADPT) reported mrd business — sales & marketing of $24.74M in Q1 2026.
- How has Adaptive Biotechnologies's mrd business — sales & marketing changed year-over-year?
- Adaptive Biotechnologies's mrd business — sales & marketing increased by 15.5% year-over-year, from $21.41M to $24.74M.
- What is the long-term trend for Adaptive Biotechnologies's mrd business — sales & marketing?
- Over 3 years (2022 to 2025), Adaptive Biotechnologies's mrd business — sales & marketing has grown at a 10.3% compound annual growth rate (CAGR), from $65.56M to $87.92M.
- What does mrd business — sales & marketing mean?
- This represents the costs associated with promoting, selling, and distributing diagnostic products to healthcare providers and institutions. It is a key indicator of the company's commercial scaling efforts and the resources deployed to capture market share in the MRD diagnostic space.